Wall Street Zen Downgrades ResMed (NYSE:RMD) to Hold
ResMed (NYSE:RMD – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday. A number of other brokerages have also commented on RMD. UBS Group cut their price target on ResMed from $290.00 to $285.00 and set a […]
ResMed (NYSE:RMD – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday. A number of other brokerages have also commented on RMD. UBS Group cut their price target on ResMed from $290.00 to $285.00 and set a […]
